]>
IRCT20241010063323N1 IRCT 2025-10-26 Shahid Beheshti University of Medical Sciences effect of Dienogest in reduction of pelvic pain in endometriosis; continuous Combined Oral Contraceptive(COC) in pelvic pain of endometriosis Comparison of the effect of Dienogest and continuous Combined Oral Contraceptive(COC) in reduction of pelvic pain in endometriosis 2025-05-22 anticipated 128 Complete https://irct.ir/trial/80951 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this research, simple randomization is done with the help of a table of random numbers. 3 endometriosis. Intervention 1: Intervention group: The first group is treated with 2 mg of Verogest, one tablet every night for 180 days without forgetting. Intervention 2: Intervention group: The second group is treated with an oral contraceptive pill containing 0.03 micrograms of ethinyl estradiol and 2 mg of dienogest, one effective pill every night without forgetting for 180 days. Yes - There is a plan to make this available What will be shared: Shared files: Participant data file, study protocol, statistical analysis map, informed consent form, clinical study report, codes used in analysis and data classification system. All data can be shared after de-identification. When: Access period starts 6 months after results are published To whom: Only for researchers working in academic and scientific institutions Conditions: In order to use the data in therapeutic work and also to conduct further studies Where to obtain: Applicants should visit the following email address to receive data: idaluxurious@gmail.com How to obtain: Applicants should visit the following email address to receive data: idaluxurious@gmail.com Applicants must first provide information about their research field and the purpose for which they want these files, and after review by me, if deemed appropriate, the files will be made available to the applicant. Comments:
public Aida Mazloomi
Eerabi Ave.
Tehran Iran (Islamic Republic of) 1985717413 +98 21 2243 2570 idaluxurious@gmail.com Shahid Beheshti University of Medical Sciences scientific Aida Mazloomi
Eerabi Ave.
Tehran Iran (Islamic Republic of) 1985717413 +98 21 2243 2570 idaluxurious@gmail.com Shahid Beheshti University of Medical Sciences Iran (Islamic Republic of) known case of endometriosis, and the diagnosis of endometriosis disease has been radiologically confirmed by the center's skilled sonographer with endometriosis mapping sonography or MRI or by surgery. Symptoms of pelvic pain are mentioned as moderate to severe. Women in the age group of 18 to 45 years 18 years 45 years Female The presence of symptoms related to pelvic infections GNRH agonist use in the past 3 months Pap smear or abnormal pelvic pathology The presence of contraindications to the use of hormonal drugs Desire to become pregnant within the next four months Presence of surgical indication for endometriosis in the patient Use of hormonal drugs in the past month N80 Endometriosis Treatment - Drugs Treatment - Drugs Intervention group: The first group is treated with 2 mg of Verogest, one tablet every night for 180 days without forgetting. Intervention group: The second group is treated with an oral contraceptive pill containing 0.03 micrograms of ethinyl estradiol and 2 mg of dienogest, one effective pill every night without forgetting for 180 days. Endometriosis related pelvic pain. Timepoint: To assess the level of pelvic pain caused by endometriosis at the beginning of the study and 30, 90, and 180 days later. Method of measurement: verbal rating scale and visual analogue scale. Shahid Beheshti University of Medical Sciences Approved 2024-08-21 Ethics committee of Shahid Beheshti Medical University Eerabi avenue, Taleghani hospital Tehran Tehran Iran (Islamic Republic of)